Zarhin D, Negev M, Vulfsons S, Sznitman SR. “Medical cannabis” as a contested medicine: fighting over epistemology and morality. Sci Technol Hum Values. 2020;45(3):488–514.
Fletcher B, Gheorghe A, Moore D, Wilson S, Damery S. Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review. BMJ Open. 2012;2:e000496.
Graham M, Lucas CJ, Schneider J, Martin JH, Hall W. Translational hurdles with cannabis medicines. Pharmacoepidemiol Drug Saf. 2020;29(10):1325–30.
Martin JH, Hill C, Walsh A, Efron D, Taylor K, Kennedy M, et al. Clinical trials with cannabis medicines—guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: considerations from the Australian experience. Trials. 2020;21(1):1–7.
LeBlanc TW, Lodato JE, Currow D, Abernethy AP. Overcoming recruitment challenges in palliative care clinical trials. J Oncol Pract. 2013;9(6):277–82.
Briel M, Olua KK, Ev E, Kasenda B, Alturki R, Agarwal A, et al. A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. J Clin Epidemiol. 2016;80:8–15.
Houghton C, Dowling M, Meskell P, Hunter A, Gardner H, Conway A, et al. Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis. Cochrane Database Syst Rev. 2020;10(10):MR000045.
Phelps EE, Tutton E, Griffin X, Baird J. A mixed-methods systematic review of patients’ experience of being invited to participate in surgical randomised controlled trials. Soc Sci Med. 2020;253:112961.
Caldwell PHY, Hamilton S, Tan A, Craig JC. Strategies for increasing recruitment to randomised controlled trials: systematic review. PLoS Med. 2010;7(11):e1000368.
Prout HC, Barham A, Bongard E, Tudor-Edwards R, Griffiths G, Hamilton W, et al. Patient understanding and acceptability of an early lung cancer diagnosis trial: a qualitative study. Trials. 2018;19:419.
Wright JR, Whelan TJ, Schiff S, Dubois S, Crooks D, Haines PT, et al. Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. J Clin Oncol. 2004;22(21):4312–8.
Mills N, Blazeby JM, Hamdy FC, Neal DE, Campbell B, Wilson C, et al. Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients’ treatment preferences. Trials. 2014;15:323.
Scantlebury A, McDaid C, Brealey S, Cook E, Sharma H, Ranganathan A, et al. Embedding qualitative research in randomised controlled trials to improve recruitment: findings from two recruitment optimisation studies of orthopaedic surgical trials. Trials. 2021;22:461.
Husbands S, Caskey F, Winton H, Gibson A, Donovan JL, Rooshenas L. Pre-trial qualitative work with health care professionals to refine the design and delivery of a randomised controlled trial on kidney care. Trials. 2019;20:224.
Buttgereit T, Palmowski A, Forsat N, Boers M, Witham MD, Rodondi N, et al. Barriers and potential solutions in the recruitment and retention of older patients in clinical trials-lessons learned from six large multicentre randomized controlled trials. Age Ageing. 2021;50(6):1988–96.
Sedrak MS, Freedman RA, Cohen HJ, Muss HB, Jatoi A, Klepin HD, et al. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J Clin. 2021;71(1):78–92.
Parks RM, Holmes HM, Cheung K-L. Current challenges faced by cancer clinical trials in addressing the problem of under-representation of older adults: a narrative review. Oncol Ther. 2021;9(1):55–67.
Habicht DW, Witham MD, McMurdo MET. The under-representation of older people in clinical trials: barriers and potential solutions. J Nutr Health Aging. 2008;12(3):194–6.
White C, Gilshenan K, Hardy J. A survey of the views of palliative care healthcare professionals towards referring cancer patients to participate in randomized controlled trials in palliative care. Support Care Cancer. 2008;16(12):1397–405.
White CD, Hardy JR, Gilshenan KS, Charles MA, Pinkerton CR. Randomised controlled trials of palliative care – a survey of the views of advanced cancer patients and their relatives. Eur J Cancer. 2008;44(13):1820–8.
Agar M. Medicinal cannabinoids in palliative care. Br J Clin Pharmacol. 2018;84(11):2491–4.
Martin JH, Bonomo YA. Medicinal cannabis in Australia: the missing links. Med J Aust. 2016;204(10):371–3.
Mücke M, Weier M, Carter C, Copeland J, Degenhardt L, Cuhls H, et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle. 2018;9(2):220–34.
Kaufmann CN, Kim A, Miyoshi M, Han BH. Patterns of medical cannabis use among older adults from a cannabis dispensary in New York state. Cannabis Cannabinoid Res. 2020;7(2):224–30.
Kim A, Kaufmann CN, Ko R, Li Z, Han BH. Patterns of medical cannabis use among cancer patients from a medical cannabis dispensary in New York state. J Palliat Med. 2019;22(10):1196–201.
Panozzo S, Le B, Collins A, Weil J, Whyte J, Barton M, et al. Who is asking about medicinal cannabis in palliative care? Intern Med J. 2020;50(2):243–6.
Luba R, Earleywine M, Farmer S, Slavin M. Cannabis in end-of-life care: examining attitudes and practices of palliative care providers. J Psychoactive Drugs. 2018;50(4):348–54.
Wilson A, Davis C. Attitudes of cancer patients to medicinal cannabis use: a qualitative study. Aust Soc Work. 2021;75(2):192–204.
Harrop E, Walker L, Catalano RF, Haggerty K. Meds, myths, and marijuana: adolescents with CHEDS. J Adolesc Health. 2015;56(2):S28–S9.
Satterlund TS, Lee JP, Moore RS. Stigma among California’s medical marijuana patients. J Psychoactive Drugs. 2015;47(1):10–7.
Troutt WD, DiDonato MD. Medical cannabis in Arizona: patient characteristics, perceptions, and impresisons of medical cannabis legalization. J Psychoactive Drugs. 2015;47(4):259–66.
Kvamme SL, Pedersen MM, Alagem-Iversen S, Thylstrup B. Beyond the high: mapping patterns of use and motives for use of cannabis as medicine. Nordisk Alkohol Nark. 2021;38(3):270–92.
Pedersen W, Sandberg S. The medicalisation of revolt: a sociological analysis of medical cannabis users. Sociol Health Illn. 2013;35(1):17–32.
Sznitman SR, Bretteville-Jensen AL. Public opinion and medical cannabis policies: examining the role of underlying beliefs and national medical cannabis policies. Harm Reduct J. 2015;12(1):46.
Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I. Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience. J Pain Symptom Manag. 2015;49(2):223–30.
Wagner A, Polak P, Świątkiewicz-Mośny M. From community of practice to epistemic community – law, discipline and security in the battle for the legalisation of medical cannabis in Poland. Sociol Health Illn. 2021;43(2):316–35.
Caldicott D, Sinclair J, Sheridan L, Eckermann S. Medicinal cannabis and the tyranny of distance: policy reform required for optimizing patient and health system net benefit in Australia. Appl Health Econ Health Policy. 2018;16(2):153–6.
Drosdowsky A, Blaschke S, Koproski T, Fullerton S, Thackerar A, Ellen S, et al. Cancer patients’ use of and attitudes towards medicinal cannabis (vol 44, pg 650, 2020). Aust Health Rev. 2020;44(4):656–5.
Karanges EA, Suraev A, Elias N, Manocha R, McGregor IS. Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey. BMJ Open. 2018;8(7):e022101.
Lintzeris N, Driels J, Elias N, Arnold JC, McGregor IS, Allsop DJ. Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMS-16). Med J Aust. 2018;209(5):211–6.
Lintzeris N, Mills L, Suraev A, Bravo M, Arkell T, Arnold JC, et al. Medical cannabis use in the Australian community following introduction of legal access: the 2018-2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduct J. 2020;17(1):1–37.
Good P, Haywood A, Gogna G, Martin J, Yates P, Greer R, et al. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD). BMC Palliat Care. 2019;18(1):110.
Luckett T, Phillips J, Lintzeris N, Allsop D, Lee J, Solowij N, et al. Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation. Intern Med J. 2016;46(11):1269–75.
Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. Hawthorne: Aldine de Gruyter; 1967.
O’Cathain A, Thomas KJ, Drabble SJ, Rudolph A, Hewison J. What can qualitative research do for randomised controlled trials? A systematic mapping review. BMJ Open. 2013;3(6):e002889.
Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spiegelhalter D, et al. Framework for design and evaluation of complex interventions to improve health. BMJ. 2000;321(7262):694–6.
O’Cathain A, Goode J, Drabble SJ, Thomas KJ, Rudolph A, Hewison J. Getting added value from using qualitative research with randomized controlled trials: a qualitative interview study. Trials. 2014;15(1):215.
Davis K, Minckas N, Bond V, Clark CJ, Colbourn T, Drabble SJ, et al. Beyond interviews and focus groups: a framework for integrating innovative qualitative methods into randomised controlled trials of complex public health interventions. Trials. 2019;20(1):329.
Team V, Bugeja L, Weller CD. Barriers and facilitators to participant recruitment to randomised controlled trials: a qualitative perspective. Int Wound J. 2018;15:929–42.
French C, Stavropoulou C. Specialist nurses’ perceptions of inviting patients to participate in clinical research studies: a qualitative descriptive study of barriers and facilitators. BMC Med Res Methdol. 2016;16:96.
Gleeson P. The challenges of medicinal cannabis to the political legitimacy of therapeutic goods regulation in Australia. Melb Univ Law Rev. 2019;43(2):558–604.
Good PD, Greer RM, Huggett GE, Hardy JR. An open-label pilot study testing the feasibility of assessing total symptom burden in trials of cannabinoid medications in palliative care. Journal of Palliative Medicine. 2020;23(5):650–5.
Hardy J, Haywood A, Gogna G, Martin J, Yates P, Greer R, et al. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: A double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Trials. 2020;21:611.
Melnikov S, Aboav A, Shalom E, Phriedman S, Khalaila K. The effect of attitudes, subjective norms and stigma on health-care providers’ intention to recommend medicinal cannabis to patients. Int J Nurs Pract. 2021;27(1):e12836–n/a.
Gardiner KM, Singleton JA, Sheridan J, Kyle GJ, Nissen LM. Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis - a systematic review. PLoS One. 2019;14(5):e0216556.
Ryan JE, McCabe SE, Boyd CJ. Medicinal cannabis: policy, patients, and providers. Policy Polit Nurs Pract. 2021;22(2):126–33.
Low J. Unstructured interviews and health research. In: Saks M, Allsop J, editors. Research health: Qualitative, quantitative and mixed methods. London: Sage; 2007. p. 74–91.
Cardenas V, Rahman A, Giuloni J, Coulourides Kogan A, Enguidanos S. Patient and physician perspectives on engaging in palliative and healthcare trials: a qualitative descriptive study. BMC Palliat Care. 2021;20(158):1–11.
Guetterman T. Descriptions of sampling practices within five approaches to qualitative research in education and the health sciences. Forum Qual Soc Res. 2015;16:25.
Charmaz K. Constructing grounded theory: a practical guide through qualitative analysis. Thousand Oaks: Sage; 2006.
Braun V, Clarke V. Reflecting on reflexive thematic analysis. Qual Res Sport Exerc Health. 2019;11(4):589–97.
Braun V, Clarke V. Thematic analysis. In: Cooper H, Camic P, Long D, Panter AT, Rindskopf D, Sher K, editors. APA handbook of research methods in psychology. 2nd ed. Washington, D. C.: American Psychological Association; 2012. p. 57–71.
Marks DF, Yardley L. Content and thematic analysis. In: Marks DF, Yardley L, editors. Research methods for clinical and health psychology. London: Sage Publications; 2004. p. 56–69.
Olson R, Smith A, Good P, Dudley M, Gurgenci T, Hardy J. Patient perspectives on the future of medicinal cannabis in Australia: Financial barriers, regulation, and overcoming stigma. Health Expectations. under review.
Jenkins V, Farewell D, Batt L, Maughan T, Branston L, Langridge C, et al. The attitudes of 1066 patients with cancer towards participation in randomised clinical trials. Br J Cancer. 2010;103(12):1801–7.
Dias AL, Chao JH, Lee D, Wu Y, Kloecker GH. Patient perceptions concerning clincial trials in oncology patients. Contemp Clin Trials Commun. 2016;21(4):179–85.
Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL. Patient income level and cancer clinical trial participation: a prospective survey study. JAMA Oncol. 2016;2(1):137–9.
Unger JM, Hershman DL, Albain KS, Moinpour CM, Petersen JA, Burg K, et al. Patient income level and cancer clinical trial participation. J Clin Oncol. 2013;31(5):536–42.
Price KN, Lyons AB, Hamzavi IH, Hsiao JL, Shi VY. Facilitating clinical trials participation of low socioeconomic status patients. Dermatology. 2021;237(5):843–6.
Islam MM, McRae IS, Mazumdar S, Taplin S, McKetin R. Prescription opioid analgesics for pain management in Australia: 20 years of dispensing. Intern Med J. 2016;46(8):955–63.
Ellis PM, Dowsett SM, Butow PN, Tattersall MHN. Attitudes to randomized clinical trials amongst out-patients attending a medical oncology clinic. Health Expect. 1999;2(1):33–43.
Kennedy V, Lloyd-Williams M. Maintaining hope: communication in palliative care. In: Stiefel F, editor. Communication in cancer care. Recent results in cancer research. Berlin: Springer; 2006.
Olson RE. Managing hope, denial or temporal anomie? Informal cancer carers' accounts of spouses' cancer diagnoses. Social Science & Medicine. 2011;73(6):904–11.
Kube T, Blease C, Ballou SK, Kaptchuk TJ. Hope in medicine: applying multidisciplinary insights. Perspect Biol Med. 2019;62(4):591–616.